country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-148596

Copy Link Print Information

UDP-GlcNAc

(Synonyms: UDP-N-Acetyl-D-glucosamine; Uridine diphospho-N-acetylglucosamine; UDP-N-acetylglucosamine)

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

UDP-GlcNAc (UDP-N-Acetyl-D-glucosamine) is an important component and precursor of bacterial peptidoglycan. UDP-GlcNAc is a nucleotide sugar used by Glycosyltransferases to synthesize glycoproteins, glycosaminoglycans, glycolipids, and glycoRNA. UDP-GlcNAc also serves as the donor substrate for forming O-GlcNAc, a dynamic intracellular protein modification involved in diverse signaling and disease processes. UDP-GlcNAc is the sugar nucleotide donor for the synthesis of O-GlcNAc modified proteins. UDP-GlcNAc also acts as a full agonist of the P2Y₁₄ receptor and inhibits the formation of cAMP. UDP-GlcNAc can be used in studies related to bacterial infections.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 528-04-1
Formel: C₁₇H₂₇N₃O₁₇P₂
Molecular Weight:607.35

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (275 KB)

UDP-GlcNAc Chemical Structure

CAS. Nr.: 528-04-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (8)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

P2Y14 Receptor

Alle P2Y Receptor Isoform-spezifische Produkte anzeigen :

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

In Vitro

UDP-GlcNAc acts as a full agonist of the hP2Y₁₄ receptor in P2Y₁₄-HEK293 cells, inhibiting Forskolin-stimulated cAMP accumulation with an EC₅₀ of 919 nM and a maximum inhibition rate of 58%^[2].
UDP-GlcNAc (at different concentrations; 15 min) acts as a full agonist of the hP2Y₁₄ receptor in P2Y₁₄-C6 rat glioma cells, inhibiting Forskolin-stimulated cAMP accumulation with an EC₅₀ of 225 nM and a maximum inhibition rate of 74%^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 528-04-1
Molecular Weight 607.35
Formel C₁₇H₂₇N₃O₁₇P₂
SMILES

O[C@H]1[C@@H](O)[C@H](N2C(NC(C=C2)=O)=O)O[C@@H]1COP(OP(O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)NC(C)=O)(O)=O)(O)=O
Synonyms

UDP-N-Acetyl-D-glucosamine; Uridine diphospho-N-acetylglucosamine; UDP-N-acetylglucosamine
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (8)

All Cell Proliferation/Viability AssayApoptosis AnalysisWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. [Abstract]

2023 Feb 10;8(1):63. PMID: 36765030
Cancer Res

MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma. [Abstract]

2025 Mar 14;85(6):1113-1129. PMID: 39804969

UDP-GlcNAc purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Mar 14;85(6):1113-1129. [Abstract]

MTHFD2 knockdown cells and control cells were treated with sunitinib (10 μM) and UDP-GlcNAc (10 μM) for 48 hours. Cell viability (n = 3).

UDP-GlcNAc purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Mar 14;85(6):1113-1129. [Abstract]

MTHFD2 knockdown cells and control cells were treated with sunitinib (10 μmol/L) and UDP-GlcNAc (10 μmol/L) for 48 hours. Cell apoptosis (n = 3) were used to assess the killing capacity of sunitinib. PI, propidium iodide. G, Relative levels of metabolites in MTHFD2 knockdown cells measured by untargeted metabolomics (n = 6). F6P, fructose-6-phosphate;

UDP-GlcNAc purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Mar 14;85(6):1113-1129. [Abstract]

Immunoblotting analysis of whole cell lysate (input) and His pull-down products derived from 786O cells transfected with indicated constructs and treated with MG132 (10 μmol/L) for 6 hours after cells were treated with or without UDP-GlcNAc (10 μM) for 24 hours. NC, negative control. The results showed that UDP-GlcNAc could reverse the increased c-MYC ubiquitination resulting from the silencing of MTHFD2 expression.
Plant Cell

SlSEC1- and SlSPY-mediated O-glycosylation stabilizes the transcription factor SlNOR to promote tomato fruit ripening. [Abstract]

2026 May 14:koag144. PMID: 42135064
Int J Biol Sci

O-GlcNAcylation of ZEB1 facilitated mesenchymal pancreatic cancer cell ferroptosis. [Abstract]

2022 Jun 21;18(10):4135-4150. PMID: 35844792
Dev Cell

A pathological role of O-GlcNAcylation-driven TR11B production and function in lung adenocarcinoma. [Abstract]

2025 Sep 3:S1534-5807(25)00530-1. PMID: 40930100
Mol Med

New perspectives on YTHDF2 O-GlcNAc modification in the pathogenesis of intervertebral disc degeneration. [Abstract]

2024 Oct 18;30(1):180. PMID: 39425013
PLoS Pathog

O-GlcNAcylation licenses RNF166 to degrade the M protein of porcine coronaviruses. [Abstract]

2026 Jun 25;22(6):e1014301. PMID: 42348500
Laurea Magistrale in Biomedical Engineering, Politecnico di Milano

2019 Jun.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wyllie JA, et al. Biosynthesis of uridine diphosphate N-Acetylglucosamine: An underexploited pathway in the search for novel antibiotics?. IUBMB Life. 2022;74(12):1232-1252. [Content Brief]

[2]. Fricks IP, et al. Gi-dependent cell signaling responses of the human P2Y14 receptor in model cell systems. J Pharmacol Exp Ther. 2009;330(1):162-168. [Content Brief]

[3]. Li Z, et al. Genetically Encoded Green Fluorescent Biosensors for Monitoring UDP-GlcNAc in Live Cells. ACS Cent Sci. 2021 Oct 27;7(10):1763-1770. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

UDP-GlcNAc

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (8)
Reinheit & Dokumentation
Verweise

1/16
1/16

UDP-GlcNAc purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Mar 14;85(6):1113-1129. [Abstract]

Customer Validation
MTHFD2 knockdown cells and control cells were treated with sunitinib (10 μM) and UDP-GlcNAc (10 μM) for 48 hours. Cell viability (n = 3).
1/16

UDP-GlcNAc purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Mar 14;85(6):1113-1129. [Abstract]

Customer Validation
MTHFD2 knockdown cells and control cells were treated with sunitinib (10 μmol/L) and UDP-GlcNAc (10 μmol/L) for 48 hours. Cell apoptosis (n = 3) were used to assess the killing capacity of sunitinib. PI, propidium iodide. G, Relative levels of metabolites in MTHFD2 knockdown cells measured by untargeted metabolomics (n = 6). F6P, fructose-6-phosphate;
1/16

UDP-GlcNAc purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Mar 14;85(6):1113-1129. [Abstract]

Customer Validation
Immunoblotting analysis of whole cell lysate (input) and His pull-down products derived from 786O cells transfected with indicated constructs and treated with MG132 (10 μmol/L) for 6 hours after cells were treated with or without UDP-GlcNAc (10 μM) for 24 hours. NC, negative control. The results showed that UDP-GlcNAc could reverse the increased c-MYC ubiquitination resulting from the silencing of MTHFD2 expression.

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

UDP-GlcNAc

Publications Citing Use of MedChemExpress (MCE) UDP-GlcNAc

Alle P2Y Receptor Isoform-spezifische Produkte anzeigen

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

UDP-GlcNAc Related Classifications

HY-148596 Related Classifications